eXoZymes Inc. Inc. 于2026年2月10日重新命名,将重点转向药品和营养品,利用其AI驱动的无细胞平台,促进可持续、高纯度分子生产。 eXoZymes Inc. rebranded on Feb. 10, 2026, shifting focus to pharmaceuticals and nutraceuticals using its AI-driven, cell-free platform for sustainable, high-purity molecule production.

eXoZymes Inc. 于2026年2月10日重新命名, 揭开一个新的身份和网站, eXoZymes Inc. rebranded on February 10, 2026, unveiling a new identity and website to emphasize its strategic pivot toward pharmaceuticals and high-value nutraceuticals. 该公司正在推进其AI动力、无细胞的Exozyme平台,该平台旨在生产高纯度和高一致性的复杂小分子,以强有力的知识产权保护和需求为受管制市场确定目标。 The company is advancing its AI-powered, cell-free exozyme platform—designed to produce complex small molecules with high purity and consistency—targeting regulated markets with strong IP protection and demand. 该平台旨在取代效率低下的石油化学和提取方法,支持可持续的生物制造。 The platform aims to replace inefficient petrochemical and extraction methods, supporting sustainable biomanufacturing. 该公司计划通过多功能、可扩展的技术而不是单一产品来创造长期价值,而不给“exozymes”这一术语打上商标,以鼓励整个行业采用。 The company plans to build long-term value through a versatile, scalable technology rather than a single product, without trademarking the term "exozymes" to encourage industry-wide adoption.